Sökning: "Lung cancer"

Visar resultat 6 - 10 av 345 avhandlingar innehållade orden Lung cancer.

  1. 6. Body Protein and its Change in Patients During Anti-Tumor Treatment

    Författare :Lianna Kadar; Malmö Institutionen för kliniska vetenskaper; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Cytology; Gastrointestinal tumors; Breast cancer; Lung cancer; Prognosis; Body protein; oncology; cancerology; Cytologi; onkologi; cancer;

    Sammanfattning : The purpose of this study was to investigate how total body protein and its fraction of body weight (body protein fraction) change in cancer patients during different anti-tumor treatments, and to see if these changes have any clinical significance in the form of prognostic value or correlation with disease course and tumor response. In 84 patients, 28 with lung cancer, 24 with gastrointestinal tumors, 30 with breast cancer, 1 with non-Hodgkin lymphoma and 1 with kidney cancer, the total amount of body nitrogen was measured using an in vivo prompt gamma neutron activation technique. LÄS MER

  3. 7. Biomarkers in mesothelioma and non-small cell lung cancer - Investigation of cytological specimens with correlation to histology

    Författare :Mohammed S. I. Mansour; LUCC: Lunds universitets cancercentrum; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Biomarker; Cytology; Cytology-histology correlation CHC ; Cytopathology; Effusion cytology; Genetic alteration; Histology; Histopathology; Immunohistochemistry; Immunotherapy; Lung cancer; Lung cytology; Mesothelioma; Molecular analysis; Non-small cell lung cancer; Oncologic pathology; Therapeutic pathology;

    Sammanfattning : .... LÄS MER

  4. 8. Improving the diagnostic armamentarium of lung cancer

    Författare :Hedvig Elfving; Patrick Micke; Fredrik Pontén; Marika Nestor; Reinhard Büttner; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; lung cancer; tissue microarray; immunohistochemistry; targeted therapy; immunotherapy; checkpoint inhibitors; immune microenvironment; prognosis; biomarkers; immune cells.;

    Sammanfattning : Lung cancer is the leading cause of cancer-related death globally, with non-small cell lung cancer (NSCLC) constituting 85% of cases. The introduction of immunotherapies and targeted therapies have dramatically improved the prognosis and outcome for a subset of patients, and stressed the development of diagnostic tools for effective patient selection. LÄS MER

  5. 9. Lung Metastases - Diagnostic, Prognostic and Molecular Aspects with Focus on Colorectal Cancer

    Författare :Halla Vidarsdottir; Förbättrad diagnostik och prognostik vid lungcancer och metastaser till lunga; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; lung cancer; lung metastasis; tissue microarray; TTF-1; napsin A; cytokeratin; GATA3; CDX2; PAX8; CRC; pulmonary metastasectomy; RBM3; recurrence; survival; NGS; Trusight tumor 26; Trusight Oncology 500;

    Sammanfattning : In Sweden 4200 patients are diagnosed with lung cancer and 6500 patients with colorectal cancer (CRC) annually. The lungs are a common site for metastases. Immunohistochemistry (IHC) is a helpful aid in diagnostics of a pulmonary tumour. LÄS MER

  7. 10. Long-term effects of adjuvant tamoxifen treatment on cardiovascular disease and cancer

    Författare :Johan Rosell; John Carstensen; Olle Stål; Bo Nordenskjöld; Lars Holmberg; Linköpings universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Adjuvant; adverse events; breast cancer; cerebrovascular disease; coronary heart disease; heart failure; lung cancer; second primary cancer; tamoxifen;

    Sammanfattning : The aims of this thesis were to investigate the long-term effects of adjuvant tamoxifen treatment on breast cancer recurrence and mortality, cardiovascular disease, and the incidence of secondary cancer.Between 1982 and 1992, postmenopausal patients with early stage breast cancer were included in a randomized clinical study of 2 or 5 years of postoperative tamoxifen therapy. LÄS MER